Clinical trials · Maryland
Advanced Cancer clinical trials in Maryland
We’re tracking 137 recruiting advanced cancer studies with a site in Maryland — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Maryland
- NCT03191149RecruitingPhase 2
Osimertinib for lung cancer with an EGFR exon 20 change
This Phase 2 study tests osimertinib (a targeted lung cancer pill) in people with advanced non-small cell lung cancer (NSCLC) whose tumors have an EGFR exon 20 insertion. It aims to see how well osimertinib works for this specific EGFR mutation and how safe it is.
Baltimore, MarylandAges 18 years+ - NCT05687136RecruitingPhase 1
Study two targeted drugs for solid tumors with DNA repair changes
This Phase 1 trial tests how safe and effective two anti-cancer drugs (peposertib and tuvusertib) are for advanced solid tumors. It focuses on cancers with specific DNA repair and cell-growth gene changes, aiming to shrink tumors and improve outcomes when standard treatments have stopped working.
Bethesda, MarylandAges 18 years+ - NCT05168566RecruitingPhase 2
Sutetinib for lung cancer with a specific EGFR change
This Phase 2 study tests sutetinib capsules in people with advanced (locally advanced or metastatic) non-small cell lung cancer. It’s for tumors that have a specific, uncommon EGFR mutation, and aims to see how well the drug can control the cancer with limited prior chemotherapy.
Baltimore, MarylandAges 18 years+ - NCT06350097RecruitingPhase 3
Osimertinib with or without another drug for advanced EGFR-mutant lung cancer
This trial tests whether adding a new drug (datopotamab deruxtecan) to the standard targeted therapy osimertinib works better for advanced non-small cell lung cancer with certain EGFR mutations. It is for people who have not had chemotherapy or targeted therapy before.
Bethesda, MarylandAges 18 years+ - NCT06417814RecruitingPhase 3
Study of Dato-DXd with or without osimertinib for EGFR-mutated lung cancer
This trial tests a new drug, Dato-DXd, given alone or with osimertinib, versus standard chemotherapy for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer) that has worsened after osimertinib treatment.
Bethesda, MarylandAges 18–130 - NCT04686305RecruitingPhase 1
Test drug T-DXd plus immunotherapy, with or without chemotherapy for HER2+ lung cancer
This Phase 1 study tests the safety (and early effectiveness) of T-DXd combined with immunotherapy, sometimes also with chemotherapy, in people with advanced lung cancer that is HER2-positive. It may help if standard options have been limited or your tumor does not have certain genetic changes that already have targeted treatments.
Baltimore, MarylandAges 18 years+ - NCT04924075RecruitingPhase 2
Belzutifan for cancers linked to VHL or HIF-2α changes
This Phase 2 study tests belzutifan (MK-6482) to treat certain advanced cancers caused by specific gene or disease changes, including VHL-related tumors and HIF-2α related tumors. It may help shrink tumors or slow their growth in people whose cancer matches these genetic or disease patterns.
Baltimore, MarylandAges 12 years+ - NCT06667076RecruitingPhase 2
Amivantamab combinations for advanced EGFR-mutant lung cancer
This trial tests two treatment combinations for people with a specific type of advanced lung cancer that has an EGFR mutation. One group gets amivantamab plus lazertinib, and the other gets amivantamab plus chemotherapy. The goal is to see which combo works better.
Baltimore, MarylandAges 18 years+ - NCT04303117RecruitingPhase 1/Phase 2
Test drug PDS01ADC alone and with immunotherapy for Kaposi sarcoma
This Phase 1/2 study tests PDS01ADC, a targeted cancer drug, for advanced Kaposi sarcoma (KS). It also studies how well the drug works when added to the immunotherapy M7824, especially if KS has not responded to prior treatments.
Bethesda, MarylandAges 18–99 - NCT05733598RecruitingPhase 2
RP2 plus standard treatment for advanced liver or bile cancers
This Phase 2 trial studies whether RP2, added to standard second-line treatment, can improve outcomes for people with advanced liver cancer or bile duct/gallbladder cancer. It may help by training the immune system to better attack the cancer after the cancer has already grown despite prior treatment.
Baltimore, MarylandAges 18 years+ - NCT06692738RecruitingPhase 3
Is a new immunotherapy better than Keytruda for squamous lung cancer?
This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda), both combined with chemotherapy, as a first treatment for advanced squamous non-small cell lung cancer. It aims to see which combination works better.
Baltimore, MarylandAges 18 years+ - NCT07315113RecruitingPhase 1
Study of NXP900 plus osimertinib for EGFR lung cancer
This trial tests a new study drug called NXP900 combined with the targeted therapy osimertinib for people with advanced EGFR-mutated lung cancer who have already been treated with osimertinib. The goal is to see if the combination can help shrink tumors or slow cancer growth.
Calverton, MarylandAges 18 years+ - NCT06890338RecruitingPhase 2
Carboplatin and mirvetuximab for advanced ovarian cancer
This trial tests a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab soravtansine) given through a vein. It is for people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific protein called folate receptor alpha (FRα) on at least 75% of tumor cells.
Baltimore, MarylandAges 18 years+ - NCT05003895RecruitingPhase 1
CAR-T for solid tumors with high GPC3 protein
This early-phase trial tests a personalized CAR-T cell treatment for cancers that make a lot of a protein called GPC3. If you have advanced cancer that has already tried at least one standard treatment, and your tumor has enough GPC3, this study aims to see how well the treatment can shrink tumors and how safe it is.
Bethesda, MarylandAges 18–120 - NCT06926868RecruitingPhase 2/Phase 3
Izalontamab Brengitecan vs chemo for certain breast cancers
This trial tests a new drug called Izalontamab Brengitecan against standard chemotherapy for people with untreated advanced triple-negative or ER-low breast cancer who cannot take certain immunotherapy drugs.
Baltimore, MarylandAges 18 years+ - NCT07206888Enrolling by invitation
Study to try advanced ultrasound for breast imaging
This study explores a new way to process ultrasound images of the breast. It is for women who have a finding, cyst, mass, or calcifications seen on a mammogram or ultrasound, and it uses a special ultrasound technique that may provide clearer images without extra radiation.
Baltimore, MarylandAges 18 years+ - NCT05327010RecruitingPhase 2
Testing a new drug combination for advanced solid tumors
This trial is studying whether a new combination of two cancer drugs, ZEN003694 and talazoparib, can help people with advanced solid tumors that have not responded to other treatments. Talazoparib is a type of drug that targets cancer cells with certain DNA repair problems. The study is divided into groups based on specific gene mutations or previous treatment responses.
Bethesda, MarylandAges 18 years+ - NCT07374692Recruiting
Study of treatments for advanced brain and spinal cord tumors
This study looks at how different treatments work for people with advanced brain or spinal cord tumors that have come back. It helps doctors learn more about these tumors and how to better treat them.
Bethesda, MarylandAges 15–120 - NCT06119581RecruitingPhase 3
Oloromosib with Immunotherapy as First Treatment for KRAS G12C Lung Cancer
This trial tests a new targeted pill (olomorasib) combined with immunotherapy (pembrolizumab) and possibly chemotherapy for people with advanced non-small cell lung cancer that has a KRAS G12C mutation and has not been treated before.
Baltimore, MarylandAges 18 years+ - NCT03366116RecruitingPhase 1
Testing an epigenetic drug for advanced solid tumors
This early-phase study tests Aza-TdC in adults with advanced solid cancers that have grown despite standard treatment, or for which no standard options exist. The goal is to see if the drug can be given safely and start to show signs of benefit against tumors.
Bethesda, MarylandAges 18–120 - NCT05691491RecruitingPhase 1/Phase 2
Temozolomide plus M1774 for advanced metastatic cancers
This Phase 1/2 trial tests a combination of temozolomide and M1774 to see how safe it is and whether it can help shrink advanced cancers that have spread. It focuses on certain tumor types and specific biomarker results, and it may be an option if standard treatments have been tried or aren’t possible.
Bethesda, MarylandAges 18 years+ - NCT05579366RecruitingPhase 1/Phase 2
Study drug for advanced ovarian and other solid cancers
This Phase 1/2 trial studies Rinatabart Sesutecan to treat advanced cancers, with special focus on certain ovarian cancer types. It’s meant for people whose cancer has come back or has not responded to prior treatments.
Rockville, MarylandAges 18 years+ - NCT06793215RecruitingPhase 3
Divarasib plus pembrolizumab for KRAS G12C lung cancer
This trial compares a new targeted drug (divarasib) combined with an immunotherapy (pembrolizumab) versus standard chemotherapy plus immunotherapy for people with advanced lung cancer that has a specific KRAS G12C mutation. It aims to see if the new combination works better and is safe.
Baltimore, MarylandAges 18 years+ - NCT06655246RecruitingPhase 1
Ziftomenib and imatinib for advanced GIST
This trial tests a new drug, ziftomenib, combined with imatinib for people with advanced or spreading gastrointestinal stromal tumors (GIST) that have a KIT mutation. It may help if your GIST has gotten worse while on imatinib.
Baltimore, MarylandAges 18 years+
Advanced Cancer trials by city in Maryland
Where these studies are running in Maryland
Institutions with a site for the recruiting advanced cancer studies listed above.
- National Institutes of Health Clinical Center · 7 studies
- Research Site · 4 studies
- National Cancer Institute (NCI) · 3 studies
- Johns Hopkins University · 2 studies
- Maryland Oncology Hematology · 2 studies
- Maryland Oncology Hematology, P.A. · 2 studies
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · 2 studies
- University of Maryland Medical Center · 2 studies
What taking part in a advanced cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Advanced Cancer trials in other states
Common questions
- Are there advanced cancer clinical trials in Maryland?
- Yes. We're currently tracking 137 recruiting advanced cancer studies with a site in Maryland, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a advanced cancer study in Maryland?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Maryland to take part?
- Not necessarily. These studies have a site in Maryland, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a advanced cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New advanced cancer studies open in Maryland regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.